AstraZeneca Employee Traded On Icosavax Deal, SEC Says
The U.S. Securities and Exchange Commission on Wednesday accused a former AstraZeneca Pharmaceuticals LP employee of using nonpublic information to trade ahead of the company's $1.1 billion acquisition of vaccine design...To view the full article, register now.
Already a subscriber? Click here to view full article